当前位置: X-MOL 学术Dermatol. Ther. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

回复“关于‘Lebrikizumab 与 Dupilumab 在中度至重度特应性皮炎中的长期疗效维持和不良事件发生率的匹配调整间接比较’致编辑的信”

Dermatology and Therapy ( IF 3.5 ) Pub Date : 2024-03-05 , DOI: 10.1007/s13555-024-01107-1
Kim Rand 1 , Juan Manuel Ramos-Goñi 1 , Bülent Akmaz 2 , Laia Solé-Feu 2 , José-Carlos Armario-Hita 3
Affiliation  





"点击查看英文标题和摘要"

更新日期:2024-03-05
down
wechat
bug